echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Plant Extracts News > Ma Yinglong: increase the coverage of cosmetics business in the field of e-commerce

    Ma Yinglong: increase the coverage of cosmetics business in the field of e-commerce

    • Last Update: 2013-09-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Ma Yinglong's (600993 SH) cosmetics business saw steady growth in revenue in the first half of the year People from the company told the big smart news agency that they would increase the coverage of "Ma Yinglong Babao" and "Tong Hua" cosmetics brands in the field of e-commerce next It is estimated that with the further development of channels and the completion of product distribution, the pharmaceutical business is expected to achieve explosive growth At present, Ma Yinglong Babao is mainly sold in drugstores, and Tong dialect is mainly sold in nursing stores, among which Tong dialect has basically realized nationwide promotion "Next, in addition to deepening the coverage of the original channels, both brands will increase the promotion in the field of e-commerce (tmall mall, online drugstore)." The person said In order to expand new businesses and enhance the competitiveness of commercial sectors, Ma Yinglong has been involved in the cosmetics business around the eye product positioning since 2010, and has successively launched two brands of "Ma Yinglong Babao" and "Tong Hua" The former was listed in 2010, mainly in chain drugstores in Beijing, Wuhan, Changsha and Changchun, focusing on OTC channels; the latter was listed in the second half of 2012, focusing on franchise stores (such as Watsons and Wanning) channels The data shows that from 2010 to 2012, Ma Yinglong's pharmaceutical business achieved revenues of about 10 million, 30 million and 50 million respectively The market expects that the revenue in 2013 is expected to exceed 100 million yuan, and the company will start to contribute profits in 2014 The company's people frankly say that the current pharmaceutical revenue is lower than the market expectation, with an annual growth rate of about 50%, and will not contribute profits in the short term.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.